Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; Institute for Radiation Sciences, Osaka University.
Institute for Radiation Sciences, Osaka University; Department of Nuclear Medicine, University Hosptial Duesseldorf (UKD), Geb. 13.52.01.50, Moorenstrasse 5D-40225 Düsseldorf, Germany.
PET Clin. 2023 Jul;18(3):337-344. doi: 10.1016/j.cpet.2023.02.009. Epub 2023 Apr 6.
Like other major cancers, gastric cancer expresses fibroblast activation protein (FAP) in cancer-associated fibroblasts. Many recent studies have reported the utility and superiority of FAP inhibitor (FAPI)-PET over [F]fluorodeoxyglucose (FDG)-PET in gastric cancers, from initial staging to recurrence detection. FAPI-PET shows higher accumulation in primary sites and metastatic lesions than does FDG-PET, especially for the detection of peritoneal carcinomatosis. In the case of gastric signet ring cell carcinoma, FAPI-PET showed excellent performance, as uptake is usually weak on FDG-PET in this cohort.
与其他主要癌症一样，胃癌在癌相关成纤维细胞中表达成纤维细胞激活蛋白 (FAP)。许多最近的研究报告了 FAP 抑制剂 (FAPI)-PET 在胃癌中的实用性和优越性，从初始分期到复发检测。FAPI-PET 在原发部位和转移病变中的积累高于 FDG-PET，尤其是对腹膜癌病的检测。在胃印戒细胞癌的情况下，FAPI-PET 表现出优异的性能，因为在该队列中 FDG-PET 的摄取通常较弱。
